carbon monoxide has been researched along with Kidney Failure in 3 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Renal insufficiency, PAH associated with connective tissue disease, functional class III, mean right atrial pressure, resting systolic blood pressure and heart rate, 6-minute walk distance, brain natriuretic peptide, percent predicted carbon monoxide diffusing capacity, and pericardial effusion on echocardiogram all predicted mortality." | 5.14 | Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). ( Badesch, DB; Barst, RJ; Benza, RL; Coffey, CS; Elliott, CG; Foreman, AJ; Frantz, RP; Frost, A; Gomberg-Maitland, M; Liou, TG; McGoon, MD; Miller, DP, 2010) |
| "Using a rat model of CP-induced renal failure, we found that treatment with CP (7." | 1.33 | Protection against cisplatin-induced nephrotoxicity by a carbon monoxide-releasing molecule. ( Green, CJ; Johnson, TR; Mann, BE; Motterlini, R; Tayem, Y, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benza, RL | 1 |
| Miller, DP | 1 |
| Gomberg-Maitland, M | 1 |
| Frantz, RP | 1 |
| Foreman, AJ | 1 |
| Coffey, CS | 1 |
| Frost, A | 1 |
| Barst, RJ | 1 |
| Badesch, DB | 1 |
| Elliott, CG | 1 |
| Liou, TG | 1 |
| McGoon, MD | 1 |
| Tayem, Y | 1 |
| Johnson, TR | 1 |
| Mann, BE | 1 |
| Green, CJ | 1 |
| Motterlini, R | 1 |
| Haynes, JM | 1 |
| St Pierre, JT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Non-invasive Measurement of Cardiac Output and Stroke Volume to Assess Risk and Response to Treatment in Patients With PAH or CTEPH[NCT05618093] | 100 participants (Anticipated) | Interventional | 2023-03-02 | Enrolling by invitation | |||
| Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study[NCT03655704] | Early Phase 1 | 7 participants (Actual) | Interventional | 2019-08-22 | Completed | ||
| REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management[NCT00370214] | 3,515 participants (Actual) | Observational | 2006-03-31 | Completed | |||
| National, Prospective, Multicenter,Observational Registry Study on Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension in China[NCT01417338] | 3,079 participants (Anticipated) | Observational | 2009-08-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for carbon monoxide and Kidney Failure
2 other studies available for carbon monoxide and Kidney Failure
| Article | Year |
|---|---|
Protection against cisplatin-induced nephrotoxicity by a carbon monoxide-releasing molecule.
Topics: Animals; Carbon Monoxide; Caspase 3; Caspases; Cisplatin; Cyclic GMP; Dose-Response Relationship, Dr | 2006 |
Occult carboxyhemoglobinemia and hypoxemia in a patient with malaria.
Topics: Acidosis; Adolescent; Anemia, Hemolytic; Blood Gas Analysis; Carbon Monoxide; Carboxyhemoglobin; Con | 2000 |